Corient Private Wealth LLC Invests $316,000 in Inhibrx, Inc. (NASDAQ:INBX)

Corient Private Wealth LLC acquired a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 20,492 shares of the company's stock, valued at approximately $316,000. Corient Private Wealth LLC owned approximately 0.14% of Inhibrx as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. acquired a new position in Inhibrx in the 4th quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Inhibrx in the fourth quarter worth $47,000. New York State Common Retirement Fund acquired a new stake in Inhibrx in the fourth quarter valued at $53,000. Exchange Traded Concepts LLC bought a new position in Inhibrx during the 4th quarter worth $148,000. Finally, Rhumbline Advisers acquired a new position in Inhibrx during the 4th quarter worth about $228,000. Institutional investors own 82.46% of the company's stock.

Inhibrx Trading Down 5.5 %

Shares of INBX traded down $0.77 during trading hours on Thursday, hitting $13.33. 220,446 shares of the stock were exchanged, compared to its average volume of 215,851. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $35.42. The business has a 50-day moving average of $13.39 and a 200-day moving average of $14.56.

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, sell-side analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.

Remove Ads

Analysts Set New Price Targets

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.